Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.

Mawar KarsaAngelika KosciolekAngelika BongersAnna MarianaTim FailesAndrew J GiffordUrsula R KeesLaurence C CheungRishi S KotechaGreg M ArndtMichelle HaberMurray D NorrisRosemary SuttonRichard B LockMichelle J HendersonKlaartje Somers

Published in: British journal of cancer (2021)

Our study highlights auranofin as a well-tolerated drug candidate for high-risk paediatric leukaemias that warrants further preclinical investigation for application in high-risk paediatric and adult acute leukaemias.

Keyphrases

liver failure
intensive care unit
emergency department
reactive oxygen species
drug induced
respiratory failure
aortic dissection
stem cells
hepatitis b virus
cell therapy
mesenchymal stem cells
adverse drug
young adults
acute respiratory distress syndrome